Fosun Pharmaceutical (600196.SH) announced that the company's holding subsidiary Fuhong Kanghe Pharmaceutical Jiangsu Co., Ltd. and Japan M...
Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that OP0595 (generic name: Nacubactam; “the new drug”) co-developed by the company's holding subsidiary Fuhong Kanghe Pharmaceutical Jiangsu Co., Ltd. and Japan's Meiji Seika Pharma Co., Ltd. (“Meiji Pharmaceutical”) within the region (i.e. within China, Hong Kong and Macau Special Administrative Region of China) were co-administered with cefepime or azitronam for adults with limited treatment plans (excluding China, Macao and Taiwan) (Region, same below) recently initiated two phase III clinical trials, including
(1) A phase III clinical trial evaluating the efficacy and safety of cefepime/this new drug or aztreonam/this new drug compared to imipename/cilastatin in treating complex urinary tract infections or acute simple pyelonephritis in adults, and (2) an evaluation of cefepime/this new drug and aztreonam/this new drug compared with existing best treatment methods in treating adults with complicated urinary tract infections, acute simple pyelonephritis, hospital-acquired pneumonia-related bacterial pneumonia Phase III efficacy and safety of bacterial pneumonia and complicated abdominal infections clinical trials.